Clene (CLNN) Accounts Receivable : $0.14 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Clene Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Clene's accounts receivables for the quarter that ended in Dec. 2023 was $0.14 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Clene's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 76.76.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Clene's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.03.

Clene Accounts Receivable Historical Data

The historical data trend for Clene's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Accounts Receivable Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.02

0.05

0.19

0.14

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial												0.19	0.06	0.16	0.06	0.14

Clene Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Clene Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Clene's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.143	/	0.17	*	91
=	76.76

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Clene's accounts receivable are only considered to be worth 75% of book value:

Clene's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(35	+	0.75 * 0.143	+	0.5 * 0.037	-	38.951
-	0	-	0)	/	128.423
=	-0.03

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Clene Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Clene's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (CLNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNN) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).

Executives

David J Matlin	director
Matthew Kiernan	director	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Arjun Jj Desai	director	C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Robert Dee Etherington	director, officer: Chief Executive Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
John Henry Stevens	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Chidozie Ugwumba	director	158 FILMORE STREET, DENVER CO 80206
Alison Mosca	director	26 PATRIOT PLACE, SUITE 301, FOXBORO MA 02035
Jonathon Gay	director	177 HUNTINGTON AVENUE, 21ST FLOOR, BOSTON MA 02115
General Resonance Llc	10 percent owner	6510 SOUTH MILLROCK DRIVE, SUITE 250, HOLLADAY UT 84121
Robert Glanzman	officer: Chief Medical Officer	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Morgan R Brown	officer: Chief Financial Officer	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Vallerie Mclaughlin	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Mark Mortenson	officer: Chief Science Officer	500 PRINCIPIO PARKWAY WEST, SUITE 400, NORTH EAST MD 21901
Fiona Costello	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121
Shalom Jacobovitz	director	6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY UT 84121